Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · Real-Time Price · USD
2.148
-0.022 (-1.03%)
Dec 23, 2024, 11:04 AM EST - Market open
-1.03%
Market Cap 59.09M
Revenue (ttm) n/a
Net Income (ttm) -21.89M
Shares Out 27.51M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 87,329
Open 2.160
Previous Close 2.170
Day's Range 2.050 - 2.160
52-Week Range 1.260 - 7.460
Beta 0.27
Analysts Strong Buy
Price Target 7.00 (+225.85%)
Earnings Date Nov 12, 2024

About IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislel... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2021
Employees 17
Stock Exchange NASDAQ
Ticker Symbol IMMX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for IMMX stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(225.85% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marro...

4 days ago - GlobeNewsWire

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete...

7 days ago - GlobeNewsWire

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of prior therapy in updated Phase 1/2 data as of Dece...

13 days ago - GlobeNewsWire

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management's formal remarks, there will be a question-...

14 days ago - GlobeNewsWire

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANG...

4 weeks ago - GlobeNewsWire

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses i...

2 months ago - GlobeNewsWire

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. C...

3 months ago - GlobeNewsWire

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKC...

4 months ago - GlobeNewsWire

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis $8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis

5 months ago - GlobeNewsWire

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapie...

6 months ago - GlobeNewsWire

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmu...

6 months ago - GlobeNewsWire

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201...

8 months ago - GlobeNewsWire

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for: EU proto...

8 months ago - GlobeNewsWire

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-20...

8 months ago - GlobeNewsWire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell thera...

9 months ago - GlobeNewsWire

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell t...

9 months ago - GlobeNewsWire

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United St...

10 months ago - GlobeNewsWire

Immix Biopharma 12 Month Review Progress Update

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 1...

10 months ago - GlobeNewsWire

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies f...

11 months ago - GlobeNewsWire

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU protoc...

11 months ago - GlobeNewsWire

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies f...

11 months ago - GlobeNewsWire

Immix Biopharma Announces Proposed Public Offering of Common Stock

LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today...

11 months ago - GlobeNewsWire

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapi...

11 months ago - GlobeNewsWire

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized thought leader in aut...

1 year ago - GlobeNewsWire

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior ...

1 year ago - GlobeNewsWire